Plasma Lipids as Biomarkers for Liver Disease
Author Information
Author(s): Heymann Clément J. F., Mak Anne Linde, Holleboom Adriaan G., Verheij Joanne, Shiri-Sverdlov Ronit, van Mil Saskia W. C., Tushuizen Maarten E., Koek Ger H.
Primary Institution: Amsterdam University Medical Centers
Hypothesis
Can the plasma lipidome serve as a biomarker for different stages of metabolic dysfunction-associated steatotic liver disease (MASLD)?
Conclusion
Plasma lipids may be useful as biomarkers to distinguish between stages of MASLD, particularly in differentiating individuals with metabolic dysfunction-associated steatohepatitis (MASH) from those without.
Supporting Evidence
- Individuals with MASLD had higher plasma concentrations of sphingolipids, glycerolipids, and glycerophospholipids compared to MASLD-free subjects.
- Plasma concentrations of specific lipids differed significantly between individuals with and without MASH.
- PC(36:2) concentrations may help distinguish between MASLD individuals with and without MASH.
Takeaway
This study looked at blood fats to see if they can help tell how bad liver disease is. They found some fats that might help doctors know if someone has a more serious liver problem.
Methodology
The study analyzed the plasma lipid profiles of 39 individuals, including 32 with MASLD and 7 without, using lipidomics to identify and quantify over 1600 lipids.
Potential Biases
The skewed distribution of sex and age among the groups may introduce confounding factors.
Limitations
The study had a limited sample size and an imbalance in participant demographics, which may affect the results.
Participant Demographics
Participants were predominantly Caucasian, overweight, treatment-naïve individuals with hepatic steatosis.
Statistical Information
P-Value
0.0043
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website